Akers Biosciences, Inc. Announces Adjournment of Annual Meeting to August 3, 2015

Jun. 25, 2015 12:00 pm |  More About Akers Biosciences


THOROFARE, N.J., June 25, 2015 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company"), a medical device company focused on reducing the cost of healthcare through faster, easier diagnostics, announces that it convened its Annual Meeting of Stockholders earlier today. Pursuant to the Company's by-laws, 40% of the total voting capital of the Company is required to transact business at the annual meeting. The Company did not establish a sufficient quorum and adjourned the meeting to allow stockholders additional time to vote on the proposals set forth in the Company's definitive proxy statement filed with the Securities and Exchange Commission ("SEC") on June 5, 2015. The 2015 Annual Meeting will be reconvened at 11 a.m., EDT, on August 3, 2015 at 50 South 16th Street, 57th Floor, Philadelphia, PA 19102.

The Company filed a definitive proxy statement and a definitive form of proxy card with the SEC on June 5, 2015 in connection with its solicitation of proxies to be used at the 2015 Annual Meeting (the "2015 Annual Meeting Proxy Statement"). Stockholders are urged to read the 2015 Annual Meeting Proxy Statement and other relevant documents filed with the SEC in their entirety. The 2015 Annual Meeting Proxy Statement can be obtained free of charge at the SEC's website at www.sec.gov or at the Company's website at www.akersbiosciences.com.

During the period of the adjournment, the Company will continue to solicit proxies from its stockholders with respect to all the proposals set forth in the 2015 Annual Meeting Proxy Statement. Stockholders who have already voted do not need to recast their votes. Stockholders who have not already voted are encouraged to do so. Proxies previously submitted in respect of the 2015 Annual Meeting will be voted at the reconvened meeting unless properly revoked. Only stockholders of record as of the close of business on June 4, 2015, the record date, are entitled to and are being requested to vote.

About Akers Biosciences, Inc.

Akers Biosciences develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found at www.akersbiosciences.com. Follow us on Twitter @AkersBio.

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

CONTACT: For more information:
         
         Akers Biosciences, Inc.
         Raymond F. Akers, Jr. PhD
         Executive Chairman of the Board
         Tel. +1 856 848 8698
         
         Taglich Brothers, Inc. (Investor Relations)
         Chris Schreiber
         Tel. +1 917 445 6207
         Email: cs@taglichbrothers.com
         
         finnCap (UK Nominated Adviser and Broker)
         Geoff Nash / Scott Mathieson (Corporate Finance)
         Steve Norcross (Broking)
         Tel. +44 (0)20 7220 0500
         
         Vigo Communications (Public Relations)
         Ben Simons / Fiona Henson
         Tel. +44 (0)20 7016 9570
         Email: akers@vigocomms.com

Akers Biosciences, Inc. Company Logo

<

GlobeNewswire
June 25, 2015 - 12:00 PM EDT


comments powered by Disqus

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market